Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 26;72(8):2717–2728. doi: 10.1007/s00262-023-03453-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 3 — Validation of the prognostic effects of baseline IL-6 and IL-15 levels before nivolumab initiation in the independent validation cohort. a Kaplan–Meier survival curves for PFS on the basis of IL-6 status (log-rank, P = 0.011). b Kaplan–Meier survival curves for OS on the basis of IL-6 status (log-rank, P = 3.3E-6). c Kaplan–Meier survival curves for PFS on the basis of IL-15 status (log-rank, P = 0.00065). d Kaplan–Meier survival curves for OS on the basis of IL-15 status (log-rank, P = 0.0022)